MedTrace Logo

A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC

NCT04603833 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2021-02-21

No results posted yet for this study

Summary

The aim of this trial is to evaluate SHR3680 combined with Docetaxel to improve Metastatic Castration Resistant Prostate Cancer Patients whether the patient's Time to prostate specific antigen (PSA) progression is superior to SHR3680 or Docetaxel single drug.

Conditions

  • Prostate Cancer Metastatic

Interventions

DRUG

SHR3680+Docetaxel

Participants will receive SHR3680 combined with Docetaxel

DRUG

SHR3680

Participants will receive SHR3680

DRUG

Docetaxel

Participants will receive Docetaxel

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-02
Primary Completion
2022-10-01
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04603833 on ClinicalTrials.gov